These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22676194)

  • 1. Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.
    Dias MM; McKinnon RA; Sorich MJ
    Pharmacogenomics; 2012 Jun; 13(8):889-99. PubMed ID: 22676194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
    Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
    Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
    Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
    [No Abstract]   [Full Text] [Related]  

  • 4. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.
    Zhang X; Yin JF; Zhang J; Kong SJ; Zhang HY; Chen XM
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):135-149. PubMed ID: 28585035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
    Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
    Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.
    Yan L; Wang XF; Wei LM; Nie YL; Liu JY; Zhang LR
    Int J Clin Pharmacol Ther; 2016 Mar; 54(3):193-9. PubMed ID: 26857783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.
    Hu ZY; Yu Q; Zhao YS
    Eur J Cancer; 2010 Jul; 46(10):1856-65. PubMed ID: 20335017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
    Peng H; Duan Z; Pan D; Wen J; Wei X
    Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
    Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K
    Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.
    Dias MM; Pignon JP; Karapetis CS; Boige V; Glimelius B; Kweekel DM; Lara PN; Laurent-Puig P; Martinez-Balibrea E; Páez D; Punt CJ; Redman MW; Toffoli G; Wadelius M; McKinnon RA; Sorich MJ
    Pharmacogenomics J; 2014 Oct; 14(5):424-31. PubMed ID: 24709690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
    Liu D; Li J; Gao J; Li Y; Yang R; Shen L
    BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
    Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
    Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
    Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
    Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan].
    Okazaki K; Watanabe T; Saito I; Murayama J
    Yakugaku Zasshi; 2012; 132(2):231-6. PubMed ID: 22293705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians.
    Cheng L; Li M; Hu J; Ren W; Xie L; Sun ZP; Liu BR; Xu GX; Dong XL; Qian XP
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):551-60. PubMed ID: 24448639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
    Hoskins JM; Goldberg RM; Qu P; Ibrahim JG; McLeod HL
    J Natl Cancer Inst; 2007 Sep; 99(17):1290-5. PubMed ID: 17728214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
    Biason P; Masier S; Toffoli G
    J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
    Campbell JM; Stephenson MD; Bateman E; Peters MD; Keefe DM; Bowen JM
    Pharmacogenomics J; 2017 Jan; 17(1):21-28. PubMed ID: 27503581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
    Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
    J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
    Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
    Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.